Global Oral Antiviral Medicines for COVID-19 麻豆原创 Research Report 2024

Publication ID:

PB504248623

Publication Date:

April 10, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

The global Oral Antiviral Medicines for COVID-19 market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oral Antiviral Medicines for COVID-19, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Antiviral Medicines for COVID-19.
Report Scope
The Oral Antiviral Medicines for COVID-19 market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oral Antiviral Medicines for COVID-19 market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Antiviral Medicines for COVID-19 manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Pfizer
Merck
Shionogi
Simcere Pharmaceutical
Frontier Biotechnologies
Kexing Biopharm
Segment by Type
Lagevrio
Paxlovid
Azvudine
Segment by Application
Aldult
Elder
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Antiviral Medicines for COVID-19 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Antiviral Medicines for COVID-19 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Oral Antiviral Medicines for COVID-19 麻豆原创 Overview
1.1 Product Overview and Scope of Oral Antiviral Medicines for COVID-19
1.2 Oral Antiviral Medicines for COVID-19 Segment by Type
1.2.1 Global Oral Antiviral Medicines for COVID-19 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Lagevrio
1.2.3 Paxlovid
1.2.4 Azvudine
1.3 Oral Antiviral Medicines for COVID-19 Segment by Application
1.3.1 Global Oral Antiviral Medicines for COVID-19 麻豆原创 Value by Application: (2024-2030)
1.3.2 Aldult
1.3.3 Elder
1.4 Global Oral Antiviral Medicines for COVID-19 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Oral Antiviral Medicines for COVID-19 Revenue 2019-2030
1.4.2 Global Oral Antiviral Medicines for COVID-19 Sales 2019-2030
1.4.3 Global Oral Antiviral Medicines for COVID-19 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Oral Antiviral Medicines for COVID-19 麻豆原创 Competition by Manufacturers
2.1 Global Oral Antiviral Medicines for COVID-19 Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Oral Antiviral Medicines for COVID-19 Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Oral Antiviral Medicines for COVID-19 Average Price by Manufacturers (2019-2024)
2.4 Global Oral Antiviral Medicines for COVID-19 Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oral Antiviral Medicines for COVID-19, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oral Antiviral Medicines for COVID-19, Product Type & Application
2.7 Oral Antiviral Medicines for COVID-19 麻豆原创 Competitive Situation and Trends
2.7.1 Oral Antiviral Medicines for COVID-19 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oral Antiviral Medicines for COVID-19 Players 麻豆原创 Share by Revenue
2.7.3 Global Oral Antiviral Medicines for COVID-19 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oral Antiviral Medicines for COVID-19 Retrospective 麻豆原创 Scenario by Region
3.1 Global Oral Antiviral Medicines for COVID-19 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Oral Antiviral Medicines for COVID-19 Global Oral Antiviral Medicines for COVID-19 Sales by Region: 2019-2030
3.2.1 Global Oral Antiviral Medicines for COVID-19 Sales by Region: 2019-2024
3.2.2 Global Oral Antiviral Medicines for COVID-19 Sales by Region: 2025-2030
3.3 Global Oral Antiviral Medicines for COVID-19 Global Oral Antiviral Medicines for COVID-19 Revenue by Region: 2019-2030
3.3.1 Global Oral Antiviral Medicines for COVID-19 Revenue by Region: 2019-2024
3.3.2 Global Oral Antiviral Medicines for COVID-19 Revenue by Region: 2025-2030
3.4 North America Oral Antiviral Medicines for COVID-19 麻豆原创 Facts & Figures by Country
3.4.1 North America Oral Antiviral Medicines for COVID-19 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Oral Antiviral Medicines for COVID-19 Sales by Country (2019-2030)
3.4.3 North America Oral Antiviral Medicines for COVID-19 Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oral Antiviral Medicines for COVID-19 麻豆原创 Facts & Figures by Country
3.5.1 Europe Oral Antiviral Medicines for COVID-19 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Oral Antiviral Medicines for COVID-19 Sales by Country (2019-2030)
3.5.3 Europe Oral Antiviral Medicines for COVID-19 Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral Antiviral Medicines for COVID-19 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Oral Antiviral Medicines for COVID-19 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Oral Antiviral Medicines for COVID-19 Sales by Country (2019-2030)
3.6.3 Asia Pacific Oral Antiviral Medicines for COVID-19 Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Oral Antiviral Medicines for COVID-19 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Oral Antiviral Medicines for COVID-19 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Oral Antiviral Medicines for COVID-19 Sales by Country (2019-2030)
3.7.3 Latin America Oral Antiviral Medicines for COVID-19 Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oral Antiviral Medicines for COVID-19 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Oral Antiviral Medicines for COVID-19 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Oral Antiviral Medicines for COVID-19 Sales by Country (2019-2030)
3.8.3 Middle East and Africa Oral Antiviral Medicines for COVID-19 Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oral Antiviral Medicines for COVID-19 Sales by Type (2019-2030)
4.1.1 Global Oral Antiviral Medicines for COVID-19 Sales by Type (2019-2024)
4.1.2 Global Oral Antiviral Medicines for COVID-19 Sales by Type (2025-2030)
4.1.3 Global Oral Antiviral Medicines for COVID-19 Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Oral Antiviral Medicines for COVID-19 Revenue by Type (2019-2030)
4.2.1 Global Oral Antiviral Medicines for COVID-19 Revenue by Type (2019-2024)
4.2.2 Global Oral Antiviral Medicines for COVID-19 Revenue by Type (2025-2030)
4.2.3 Global Oral Antiviral Medicines for COVID-19 Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Oral Antiviral Medicines for COVID-19 Price by Type (2019-2030)
5 Segment by Application
5.1 Global Oral Antiviral Medicines for COVID-19 Sales by Application (2019-2030)
5.1.1 Global Oral Antiviral Medicines for COVID-19 Sales by Application (2019-2024)
5.1.2 Global Oral Antiviral Medicines for COVID-19 Sales by Application (2025-2030)
5.1.3 Global Oral Antiviral Medicines for COVID-19 Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Oral Antiviral Medicines for COVID-19 Revenue by Application (2019-2030)
5.2.1 Global Oral Antiviral Medicines for COVID-19 Revenue by Application (2019-2024)
5.2.2 Global Oral Antiviral Medicines for COVID-19 Revenue by Application (2025-2030)
5.2.3 Global Oral Antiviral Medicines for COVID-19 Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Oral Antiviral Medicines for COVID-19 Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Oral Antiviral Medicines for COVID-19 Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Oral Antiviral Medicines for COVID-19 Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Oral Antiviral Medicines for COVID-19 Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Oral Antiviral Medicines for COVID-19 Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Shionogi
6.3.1 Shionogi Corporation Information
6.3.2 Shionogi Description and Business Overview
6.3.3 Shionogi Oral Antiviral Medicines for COVID-19 Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Shionogi Oral Antiviral Medicines for COVID-19 Product Portfolio
6.3.5 Shionogi Recent Developments/Updates
6.4 Simcere Pharmaceutical
6.4.1 Simcere Pharmaceutical Corporation Information
6.4.2 Simcere Pharmaceutical Description and Business Overview
6.4.3 Simcere Pharmaceutical Oral Antiviral Medicines for COVID-19 Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Simcere Pharmaceutical Oral Antiviral Medicines for COVID-19 Product Portfolio
6.4.5 Simcere Pharmaceutical Recent Developments/Updates
6.5 Frontier Biotechnologies
6.5.1 Frontier Biotechnologies Corporation Information
6.5.2 Frontier Biotechnologies Description and Business Overview
6.5.3 Frontier Biotechnologies Oral Antiviral Medicines for COVID-19 Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Frontier Biotechnologies Oral Antiviral Medicines for COVID-19 Product Portfolio
6.5.5 Frontier Biotechnologies Recent Developments/Updates
6.6 Kexing Biopharm
6.6.1 Kexing Biopharm Corporation Information
6.6.2 Kexing Biopharm Description and Business Overview
6.6.3 Kexing Biopharm Oral Antiviral Medicines for COVID-19 Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Kexing Biopharm Oral Antiviral Medicines for COVID-19 Product Portfolio
6.6.5 Kexing Biopharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral Antiviral Medicines for COVID-19 Industry Chain Analysis
7.2 Oral Antiviral Medicines for COVID-19 Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral Antiviral Medicines for COVID-19 Production Mode & Process
7.4 Oral Antiviral Medicines for COVID-19 Sales and 麻豆原创ing
7.4.1 Oral Antiviral Medicines for COVID-19 Sales Channels
7.4.2 Oral Antiviral Medicines for COVID-19 Distributors
7.5 Oral Antiviral Medicines for COVID-19 Customers
8 Oral Antiviral Medicines for COVID-19 麻豆原创 Dynamics
8.1 Oral Antiviral Medicines for COVID-19 Industry Trends
8.2 Oral Antiviral Medicines for COVID-19 麻豆原创 Drivers
8.3 Oral Antiviral Medicines for COVID-19 麻豆原创 Challenges
8.4 Oral Antiviral Medicines for COVID-19 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Pfizer
Merck
Shionogi
Simcere Pharmaceutical
Frontier Biotechnologies
Kexing Biopharm

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.